Antibodies with functionality as a new generation of translational tools designed to monitor Multiple Sclerosis (MS) at clinical and subclinical stages

Title : Antibodies with functionality as a new generation of translational tools designed to monitor Multiple Sclerosis (MS) at clinical and subclinical stages

Abstract:

Catalytic Abs (catAbs) are multivalent immunoglobulins (Igs) with a capacity to hydrolyze the antigenic (Ag) substrate. In this sense, proteolytic Abs (Ab-proteases) represent Abs to provide proteolytic effects.

Abs against myelin basic protein/MBP with proteolytic activity exhibiting sequence-specific cleavage of MBP are of great value to monitor demyelination whilst in MS. The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. And the activity of the Ab-proteases revealed significant correlation with scales of demyelination and the disability of the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive value of the tools as applicable for monitoring protocols.

Of tremendous value are Ab-proteases directly affecting remodeling of tissues with multilevel architectonics (for instance, myelin). By changing sequence specificity one may reach reduction of a density of the negative proteolytic effects within the myelin sheath and thus minimizing scales of demyelination. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be designed for the development of new catalysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases as fantastic tools of the newest generation to diagnose, to monitor, to control and to treat and rehabilitate MS patients at clinical stages and to prevent the disorder at subclinical stages in persons-at-risks to secure the efficacy of regenerative manipulations.

What will audience learn from your presentation?

• To learn more about Ab-mediated catalysis (proteolysis) as the biological phenomenon of the next-step generation and its impact in daily practice of practitioner!
• The presentation would get the audiences armed with new approaches to monitor both clinical and subclinical stages of MS in precise scenarios!
• In this translational research faculty could use the latter for setting up translational pipelines on one hand and to teach the students and postgraduate physicians on the other one!
• The findings will solve a problem of predictive diagnostics, preventive and rehabilitative measures to be applied for monitoring the MS patients, the persons-at-risks and to prevent transformation of subclinical stages of MS into clinical ones!

Biography:

Dr. Sergey Suchkov was born in Astrakhan, Russia, into a family of medical doctors. He earned his MD from Astrakhan State Medical University in 1980 and his PhD from Sechenov University in 1985. He received advanced training at the NIH (Bethesda, USA), Wills Eye Hospital (Philadelphia, USA), and several British universities under the Royal Society for Immunology. Dr. Suchkov has held numerous academic and leadership roles, including Director of the Division for Clinical Immunology & Immunobiotechnology at MONIKI, and Professor and Chair of the Department for Personalized & Precision Medicine at Sechenov University. He has also served as Vice-Director of the Institute for Biotech & Global Health at RosBioTech National University. Currently, Dr. Suchkov is Professor of Medicine & Immunology and Director of the Center for Biodesign at the N.D. Zelinskii Institute of Organic Chemistry, Russian Academy of Sciences. He also serves as R&D Director at InMedStar (Russia–UAE) and Senior Scientific Advisor to the China Hong Kong Innovation International Business Association. He is an active member of several international scientific organizations, including the New York Academy of Sciences, EPMA, ISPM, PMC, AMEE, ACS, AHA, ARVO, and ISER, and is Secretary General of the United Cultural Convention (UCC), Cambridge, UK.